Healthcare Industry News: Terumo
News Release - July 8, 2013
Terumo Begins Commercial Distribution of BSD's MicroThermX(R) Microwave Ablation System at ECIO Following Successful Training of Sales PersonnelSALT LAKE CITY--(Healthcare Sales & Marketing Network)--BSD Medical Corporation (BSDM) (the “Company” or “BSD”) reports completion of intensive training of Terumo sales personnel in preparation for the commercial launch by Terumo Europe NV (Terumo) of BSD's MicroThermX® Microwave Ablation System (MicroThermX) at the European Conference on Interventional Oncology (ECIO). BSD and Terumo conducted successful training of 80 Terumo sales personnel prior to the commercial launch. The increasing role of microwave ablation and MicroThermX were featured at ECIO. Terumo and BSD co-sponsored an educational symposium and workshops highlighting the MicroThermX, which were well attended and led to many potential customer contacts. ECIO is a comprehensive international meeting focused exclusively on the rapidly growing field of interventional oncology, a key market for BSD's microwave ablation products. Leading interventional oncology experts from over 60 countries attended the conference.
“The ECIO meeting significantly increased the profile of the Company’s line of microwave ablation products,” stated Sam Maravich, VP of Sales and Marketing BSD. “The tremendous success of the MicroThermX exhibit was evident by a constant stream of interested clinicians from around the world. The success of the meeting reflects the dynamic growth of microwave ablation throughout the world."
About BSD Medical Corporation
BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy delivered using focused radiofrequency (RF) and microwave energy. BSD’s product lines include both hyperthermia and ablation treatment systems. BSD’s hyperthermia cancer treatment systems, which have been in use for several years in the United States, Europe and Asia, are used to treat certain tumors with heat (hyperthermia), while increasing the effectiveness of other therapies such as radiation therapy. BSD’s microwave ablation system has been developed as a stand-alone therapy to employ precision-guided microwave energy to ablate (destroy) soft tissue. The Company has developed extensive intellectual property, multiple products in the market, and established distribution in the United States, Europe and Asia. Certain of the Company’s products have received regulatory approvals and clearances in the United States, Europe and China. For further information visit BSD Medical's website at www.BSDMedical.com.
About Terumo Corporation
A world leader in state-of-the-art medical devices and interventional oncology, Tokyo-based Terumo Corporation (TYO: JP:4543) reported 2012 sales of nearly $5 billion and has a market cap in excess of $8 billion. Through the sale and promotion of a high quality line of devices used for tumor embolization, the closing or blocking of blood vessels, Terumo Europe NV has established itself as a pioneer in the field of interventional oncology.
This press release may be deemed to contain forward-looking statements, which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including the expected use of proceeds relating to the recently completed offering. Readers are cautioned that these forward-looking statements are only predictions and may differ materially from actual future events or results due to a variety of factors, including, among other things, the demand for the Company’s products, the ability of the Company to produce the products to meet the demand, global economic conditions and uncertainties in the geopolitical environment and other risk factors set forth in the Company’s most recent reports on Form 10-K and Form 10-Q. Any forward-looking statements in this release are based on limited information currently available to the Company, which is subject to change, and the Company will not necessarily update the information.
Source: BSD Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.